Characteristics of Treated Hypertension in Incident Hemodialysis and Peritoneal Dialysis Patients

American Journal of Kidney Diseases

Volumn 42, Issue 6, 2003, Pages 1260-1269

  Griffith, Todd F ^a   Chua, Benjamin S Y ^b   Allen, Andrew S ^b   Klassen, Preston S ^b   Reddan, Donal N ^b   Szczech, Lynda A ^b  

^a Metrolina Nephrology Associates   (United States)

^b NONE

Author keywords

Drug therapy; End stage renal disease (ESRD); Hypertension; Mortality

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; BEPRIDIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CLONIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENALAPRIL; FELODIPINE; FOSINOPRIL; GUANABENZ; GUANFACINE; HYDRALAZINE; ISRADIPINE; LISINOPRIL; LOSARTAN; MECAMYLAMINE; METHYLDOPA; MINOXIDIL; NICARDIPINE; NIMODIPINE; NISOLDIPINE; PRAZOSIN; RESERPINE; TERAZOSIN; UNINDEXED DRUG; VERAPAMIL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONFIDENCE INTERVAL; FEMALE; HAZARD ASSESSMENT; HEART DEATH; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERITONEAL DIALYSIS; TREATMENT OUTCOME;

EID: 0345724730     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2003.08.028     Document Type: Article

References (28)

1. Rocco MV, Yan G, Heyka RJ, et al: Risk factors for hypertension in chronic hemodialysis patients: Baseline data from the HEMO study. Am J Nephrol 21:280-288, 2001
2. USRDS 2001 Annual Data Report. Atlas of End-Stage Renal Disease in the United States. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2001
3. Psaty BM, Heckbert SR, Koepsell TD, et al: The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 274:620-625, 1995
4. Yusuf S, Sleight P, Pogue J, et al: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145-153, 2000
5. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288:2981-2987, 2002
6. Kestenbaum B, Gillen DL, Sherrard DJ, et al: Calcium channel blocker use and mortality among patients with end-stage renal disease. Kidney Int 61:2157-2164, 2002
7. Foley RN, Herzog CA, Collins AJ: Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int 62:1784-1790, 2002
8. Efrati S, Zaidenstein R, Dishy V, et al: ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis 40:1023-1029, 2002
9. McCullough PA, Sandberg KR, Yee J, et al: Mortality benefit of angiotensin-converting enzyme inhibitors after cardiac events in patients with end-stage renal disease. J Renin Angiotensin Aldosterone Syst 3:188-191, 2002
10. Duranti E, Imperiali P, Sasdelli M: Is hypertension a mortality risk factor in dialysis? Kidney Int Suppl 55:S173-S174, 1996
11. Klassen PS, Lowrie EG, Reddan DN, et al: Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA 287:1548-1555, 2002
12. Zager PG, Nikolic J, Brown RH, et al: "U" curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int 54:561-569, 1998 (erratum 54:1417, 1998)
13. Port FK, Hulbert-Shearon TE, Wolfe RA, et al: Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis 33:507-517, 1999
14. USRDS: Researcher's Guide to the USRDS Database. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2002
15. Zazgornik J, Biesenbach G, Forstenlehner M, et al: Profile of antihypertensive drugs in hypertensive patients on renal replacement therapy (RRT). Clin Nephrol 48:337-340, 1997
16. Espeland MA, Kumanyika S, Kostis JB, et al: Antihypertensive medication use among recruits for the Trial of Nonpharmacologic Interventions in the Elderly (TONE). J Am Geriatr Soc 44:1183-1189, 1996
17. Siegel D, Lopez J: Trends in antihypertensive drug use in the United States: Do the JNC V recommendations affect prescribing? Fifth Joint National Commission on the Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 278:1745-1748, 1997
18. Nichol MB, Margolies JE, Gill MA: Factors associated with antihypertensive prescribing. Ann Pharmacother 31:154-159, 1997
19. Nelson CR, Knapp DA: Trends in antihypertensive drug therapy of ambulatory patients by US office-based physicians. Hypertension 36:600-603, 2000
20. Freemantle N, Cleland J, Young P, et al: beta Blockade after myocardial infarction: Systematic review and meta regression analysis. BMJ 318:1730-1737, 1999
21. Packer M, Bristow MR, Cohn JN, et al: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334:1349-1355, 1996
22. Pfeffer MA, Braunwald E, Moye LA, et al: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327:669-677, 1992
23. Flather MD, Yusuf S, Kober L, et al: Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355:1575-1581, 2000
24. Cohn JN, Johnson G, Ziesche S, et al: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325:303-310, 1991
25. MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001-2007, 1999
26. McCullough PA, Sandberg KR, Borzak S, et al: Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. Am Heart J 144:226-232, 2002
27. Knoll GA, Sahgal A, Nair RC, et al: Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients. Am J Med 112:110-114, 2002
28. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 157:2413-2446, 1997 (erratum 158:573, 1998)